Vistella (Calcifediol) in Australia: Monthly Vitamin D for Deficiency

Vistella is now TGA-approved as Australia's first high-strength calcifediol preparation. This once-monthly vitamin D treatment offers pharmacists a new option for patients who don't respond adequately to standard cholecalciferol supplementation.

This guide covers everything pharmacists need to know about calcifediol — what it is, how it differs from standard vitamin D, who should receive it, dosing, PBS status, monitoring, and counselling points.

What is Calcifediol? Understanding 25-Hydroxyvitamin D3

Calcifediol is 25-hydroxyvitamin D3 (25(OH)D3) — the metabolite your liver produces when it processes cholecalciferol (vitamin D3). When pathology labs measure a patient's "vitamin D level," they're measuring serum 25(OH)D concentrations.

This distinction matters clinically. Standard cholecalciferol (vitamin D3) must undergo two conversion steps before becoming active:

1. Hepatic 25-hydroxylation: Cholecalciferol → 25(OH)D3 (calcifediol) — occurs in the liver
2. Renal 1α-hydroxylation: 25(OH)D3 → 1,25(OH)2D3 (calcitriol) — occurs in the kidneys

Calcifediol bypasses step 1 entirely, because it is already the 25-hydroxylated form. This results in:

• More predictable intestinal absorption — calcifediol is more hydrophilic (water-soluble) than cholecalciferol
• Faster elevation of serum 25(OH)D levels — 1–2 weeks versus 6–8 weeks for cholecalciferol
• Consistent dose-response regardless of baseline vitamin D status, body weight, or hepatic function
• Less sequestration in adipose tissue — important for obese patients

How Calcifediol Differs from Cholecalciferol (Standard Vitamin D)

Feature	Cholecalciferol (Vitamin D3)	Calcifediol (25(OH)D3)
Common brands	Ostelin, Blackmores, various OTC	Vistella
Scheduling	Unscheduled (OTC) / S3 (high dose)	S4 — Prescription Only
Hepatic conversion needed	Yes — requires CYP2R1/CYP27A1	No — already 25-hydroxylated
Absorption	Fat-soluble, variable absorption	More hydrophilic, predictable absorption
Time to raise serum 25(OH)D	6–8 weeks	1–2 weeks
Adipose sequestration	Significant in obese patients	Minimal
Affected by liver disease	Yes — impaired conversion	No — bypasses liver step
Affected by CYP450 interactions	Yes	Minimal
Potency vs cholecalciferol	1× (reference)	~3.2× at standard doses; 5.5–12× at higher doses
Dosing frequency	Daily or weekly	Monthly
Hypercalcaemia risk	Low at standard doses	Higher — hence S4 scheduling

For most patients with straightforward vitamin D deficiency, over-the-counter cholecalciferol remains appropriate, effective, and cost-efficient. Vistella fills a specific therapeutic gap.

TGA Approval and Scheduling Details

Vistella received TGA approval on 9 July 2025 and was registered in the Australian Register of Therapeutic Goods (ARTG) on 6 March 2025.

Detail	Information
Active ingredient	Calcifediol 255 micrograms (equivalent to approximately 10,200 IU vitamin D activity)
Sponsor	Aspen Pharmacare Australia Pty Ltd
Scheduling	S4 — Prescription Only Medicine
Black Triangle	Yes — enhanced reporting for 5 years from listing
ARTG number	413380
Formulation	Soft capsule for oral administration

The Black Triangle designation means pharmacists should actively report any suspected adverse events through the TGA's adverse event reporting system. This applies for 5 years from listing.

PBS Listing Status and Eligibility

As of early 2026, Vistella is available on private prescription. Pharmacists should check the PBS Schedule (pbs.gov.au) for the most current listing status, as PBS submissions may be under review.

Currently, patients pay the full private prescription cost. This contrasts with cholecalciferol, which is available over-the-counter at relatively low cost, making the cost-benefit discussion an important part of counselling.

Who Should Be Considered for Calcifediol (Rather Than Standard Vitamin D)

Calcifediol is not a replacement for routine cholecalciferol supplementation. It is indicated when standard vitamin D supplementation proves inadequate or inappropriate:

1. Malabsorption syndromes — inflammatory bowel disease, coeliac disease, post-bariatric surgery, pancreatic insufficiency, short bowel syndrome
2. Hepatic impairment — patients with liver disease who have impaired 25-hydroxylation
3. Obesity with poor response to cholecalciferol — adipose sequestration reduces cholecalciferol effectiveness
4. CYP450 drug interactions — patients on rifampicin, phenytoin, carbamazepine, ketoconazole, or ritonavir
5. Severe deficiency requiring rapid correction — calcifediol raises levels in 1–2 weeks versus 6–8 weeks
6. Persistent deficiency despite adequate cholecalciferol doses — patients who remain deficient despite compliant supplementation

Dosing: The Monthly Dosing Advantage

Standard Dosing for Vitamin D Deficiency

255 micrograms (one capsule) once monthly, taken orally with or without food.

Severe Vitamin D Deficiency

For patients with baseline 25(OH)D less than 12 ng/mL (30 nmol/L):

• One capsule per fortnight until serum levels normalise
• Then transition to monthly maintenance dosing
• Recheck serum 25(OH)D after 3 months of treatment

Why Monthly Dosing Matters

Monthly administration offers significant advantages over daily or weekly regimens:

• Adherence: Once-monthly dosing produces more stable serum 25(OH)D concentrations without the peaks and troughs seen with weekly high-dose cholecalciferol
• Simplicity: One capsule per month is easier for patients to remember than daily tablets
• Compliance rates: Monthly dosing schedules consistently show higher adherence rates than daily dosing in clinical studies
• Reduced hypercalcaemia risk: Smooth pharmacokinetic profile avoids the concentration spikes associated with intermittent high-dose regimens

Dosing Equivalence and Potency

Calcifediol is approximately 3.2 times more potent than cholecalciferol at standard doses. At higher doses (above 2000 IU cholecalciferol equivalent), the difference increases to 5.5–12 times greater potency.

This increased potency explains the S4 scheduling — hypercalcaemia risk is higher than with over-the-counter vitamin D supplements. Patients should never take additional high-dose vitamin D supplements alongside Vistella without medical supervision.

Monitoring: Serum 25(OH)D Levels

When to Monitor

Timepoint	Purpose
Baseline (before starting)	Confirm deficiency and severity
3 months after starting treatment	Assess response and guide ongoing dosing
Annually once stable	Ensure maintenance of adequate levels
After dose change (3 months later)	Confirm new dose is appropriate

Target Serum 25(OH)D Levels

Level	Classification
<30 nmol/L (<12 ng/mL)	Severe deficiency — consider fortnightly dosing
30–49 nmol/L (12–19 ng/mL)	Moderate deficiency
50–74 nmol/L (20–29 ng/mL)	Mild deficiency / insufficiency
≥50 nmol/L (≥20 ng/mL)	Adequate for most people
>250 nmol/L (>100 ng/mL)	Potentially toxic — risk of hypercalcaemia

Note: Some guidelines recommend a target of ≥75 nmol/L for optimal bone health. Discuss the target with the prescriber.

Additional Monitoring

• Serum calcium: Check at baseline and periodically, especially in patients at risk of hypercalcaemia
• Serum phosphate: May be relevant in patients with renal impairment
• Renal function: Important in patients with CKD — calcifediol metabolites may accumulate

Pharmacist Role in Vitamin D Management

Pharmacists are uniquely positioned to identify patients who may benefit from calcifediol and to optimise vitamin D management:

Screening and Identification

• Ask about persistent deficiency — patients who repeatedly present with low vitamin D despite cholecalciferol supplementation may benefit from calcifediol
• Identify risk factors — malabsorption, liver disease, obesity, enzyme-inducing medications
• Review medication history — CYP450 inducers (rifampicin, phenytoin, carbamazepine) can impair cholecalciferol conversion
• Check for duplicate therapy — patients should not take high-dose cholecalciferol alongside Vistella

Counselling at Dispensing

• Explain that calcifediol is a different form of vitamin D that their body can use more directly
• Emphasise monthly dosing — same day each month for consistency
• Advise on the importance of follow-up blood tests at 3 months
• Warn about symptoms of vitamin D toxicity (hypercalcaemia)
• Discuss dietary calcium intake (1000–1300mg daily) needed for vitamin D effectiveness

OTC Interactions

• When patients on Vistella come to purchase additional vitamin D supplements, counsel against concurrent high-dose supplementation
• Low-dose multivitamins containing vitamin D are generally acceptable but should be discussed with the prescriber

Patient Counselling Points for Vistella

Administration

• Take one capsule on the same day each month
• Can be taken with or without food
• Swallow whole — do not crush or chew
• If you miss a dose, take it as soon as you remember; then resume monthly dosing from the new date

Why This Form of Vitamin D?

• Explain that calcifediol is "pre-activated" vitamin D — the form your liver normally produces
• Their body can use it directly without liver processing
• It may work better than standard vitamin D for their specific condition
• It is more potent than regular vitamin D, which is why it requires a prescription

Warning Signs of Vitamin D Toxicity (Hypercalcaemia)

• Nausea, vomiting, poor appetite
• Constipation
• Weakness, fatigue
• Excessive thirst and frequent urination
• Confusion or difficulty concentrating
• Seek medical attention promptly if these occur

Calcium Intake

• Adequate dietary calcium (1000–1300mg daily) is needed for vitamin D to work effectively
• Good sources: dairy products, fortified plant milks, tinned fish with bones, green leafy vegetables
• Discuss calcium supplements if dietary intake is insufficient

Contraindications and Precautions

Contraindications

• Hypercalcaemia — pre-existing elevated serum calcium
• Hypervitaminosis D — already elevated vitamin D levels
• Known hypersensitivity to calcifediol or excipients

Use With Caution

• Renal impairment: Reduced clearance of 25(OH)D metabolites — more frequent monitoring needed
• Granulomatous diseases: Sarcoidosis, tuberculosis — increased vitamin D sensitivity due to extra-renal 1α-hydroxylation
• Concurrent thiazide diuretics: Increased hypercalcaemia risk (reduced renal calcium excretion)
• Cardiac glycosides: Hypercalcaemia potentiates digoxin toxicity
• Concurrent high-dose calcium supplements: Increased hypercalcaemia risk

Place in Therapy: Where Vistella Fits

Clinical Scenario	First-Line	Consider Calcifediol
Routine vitamin D deficiency	Cholecalciferol OTC	No
Malabsorption syndrome	Cholecalciferol trial	If inadequate response
Liver disease	—	Yes — first-line
Obesity with poor response	Cholecalciferol trial	If target not achieved
CYP450 drug interactions	—	Yes — consider early
Rapid correction needed	—	Yes — faster onset
Persistent deficiency on cholecalciferol	Review compliance/dose	If confirmed refractory

Key Takeaways for Pharmacists

1. Vistella = calcifediol 255mcg — the 25-hydroxylated (pre-activated) form of vitamin D
2. Monthly dosing simplifies adherence versus daily/weekly regimens
3. Best candidates: malabsorption, liver disease, obesity, CYP450 interactions, need for rapid correction, persistent deficiency on cholecalciferol
4. S4 scheduling — prescription required; higher potency than OTC vitamin D means greater hypercalcaemia risk
5. Black Triangle medicine — enhanced adverse event reporting for 5 years
6. Monitor serum 25(OH)D at baseline, 3 months, then annually
7. Not a replacement for standard cholecalciferol in routine deficiency
8. Pharmacists should screen for patients who might benefit — persistent deficiency, malabsorption, liver disease, enzyme-inducing medications

For more pharmacy exam preparation resources, visit our OPRA exam preparation or subscribe for full access.

---

References: TGA Australian Public Assessment Report (AusPAR) for Vistella (July 2025), Vistella Product Information (PI), PBS Schedule (pbs.gov.au), Australian Medicines Handbook (AMH), Australian Prescriber — Calcifediol high-strength formulation for vitamin D deficiency